<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664050</url>
  </required_header>
  <id_info>
    <org_study_id>LOD</org_study_id>
    <nct_id>NCT03664050</nct_id>
  </id_info>
  <brief_title>Laparoscopic Ovarian Drilling Versus Letrozole In Clomiphene Citrate Resistant Polycystic Ovary</brief_title>
  <official_title>Laparoscopic Ovarian Drilling Versus Letrozole In Clomiphene Citrate Resistant Polycystic Ovary: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work is to compare the clinical outcomes of letrozole with laparoscopic
      ovarian drilling (LOD) in patients with clomiphene-citrate-resistant polycystic ovary
      syndrome (PCOS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OVULATION RATE</measure>
    <time_frame>7 DAYS BEFORE NEXT MENSES</time_frame>
    <description>SERUM PROGESTERON LEVEL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BIOCHEMICAL PREGNANCY RATE</measure>
    <time_frame>AFTER 30 DAYS OF INTERVENTION</time_frame>
    <description>BY SERUM HCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLINICAL PREGNANCY RATE</measure>
    <time_frame>AT 6 WEEKS GESTATION</time_frame>
    <description>BY FETAL HEART RATE MONITORING BY ULTRASOUND SCAN</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Induction of Ovulation</condition>
  <arm_group>
    <arm_group_label>Group A Letrozole group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg letrozole oral tablets will be administered on the 2nd -3rd day of menses and then every day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B laparoscopic ovarian drilling group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group A 2.5 mg letrozole oral tablets</intervention_name>
    <description>2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.</description>
    <arm_group_label>Group A Letrozole group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic ovarian drilling</intervention_name>
    <description>Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.</description>
    <arm_group_label>Group B laparoscopic ovarian drilling group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients diagnosed as PCOS according to Roterdam (2003) criteria

          2. patients with Clomiphene resistance, i.e. failure to ovulate following 100 mg CC for 5
             days for at least three cycles.

          3. patent fallopian tubes, confirmed by hysterosalpingography or hysteroscopic diagnosis.

          4. normal semen analysis parameters of the patients' spouses according to the modified
             criteria of the World Health Organization.

          5. normal serum prolactin, thyroid stimulating hormone and 17-OH progesterone.

          6. no systemic disease; no gonadotropin or other hormonal drug treatment during the
             preceding 3 months.

        Exclusion Criteria:

        1- Infertility induced by reasons other than PCOS. 2- uterine cavity lesions or ovarian
        cyst. 3- &gt;40 years old. 4- body mass index (BMI) &gt;26 kg/m2. 5- contraindications to general
        anesthesia. 6- history of pelvic surgery. 7- other endocrine diseases. 8- a history of
        liver or kidney disease.

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Abdelshafy, MD</last_name>
    <phone>00201223266380</phone>
    <email>ahmedshafy@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain shams university maternity hospital</name>
      <address>
        <city>Cairo</city>
        <zip>25187</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed A Elshahawy, MD</last_name>
      <phone>+201223266380</phone>
      <email>ahmedshafy@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>September 7, 2018</last_update_submitted>
  <last_update_submitted_qc>September 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Abdel Shafy El Shahawy</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>letrozol</keyword>
  <keyword>laparoscopic ovarian drilling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

